$BMY

Novartis (NVS) and Bristol-Myers Squibb (BMY) paused CAR-T cell therapy trials. NVS halted eight studies after three patient deaths, while BMY paused enrollment due to reversible inflammatory events. NVS's oncology trials continue. BMY's situation is less severe, with no deaths reported. Both companies face safety and development risks, with potential delays and increased costs.

The Women in AI Healthcare event, hosted by Real Chemistry and Pharma Brands, discussed AI's role in healthcare, featuring female leaders from Cignpost, Microsoft, and GSK. Key topics included AI's progress in medicine, its impact on clinical settings, and the underrepresentation of women in AI and clinical studies.

Big pharma faces a $300B patent cliff by 2030, but AI-driven drug discovery, M&A, and favorable FDA policies offer growth opportunities. Key companies like Eli Lilly (LLY), J&J (JNJ), and McKesson (MCK) show varied performance. LLY's revenue tripled from 2021 to 2025, while MCK offers 24.3% fair value upside.

Bristol-Myers Squibb (BMY) reported Phase 3 data for Sotyktu in psoriatic arthritis, expanded access to ZENBEXUS, and affirmed a quarterly dividend of $0.63. Analysts upgraded the stock to 'Strong Buy', citing potential upside and long-term growth prospects despite revenue and earnings declines forecasted over the next three years.

Bristol Myers Squibb (BMS) presented Phase 3 EXCALIBER-RRMM trial data showing iberdomide (ZENBEXUS) with daratumumab and dexamethasone achieved higher MRD-negative CR rates (41%) vs. standard therapy (21%) in relapsed/refractory multiple myeloma. The FDA granted accelerated approval for this combination in August 2026. Trial continues evaluating PFS and safety.

Bristol-Myers Squibb (BMY) selected Onco360 to distribute its newly approved multiple myeloma drug, ZENBEXUS, through a restricted pharmacy network. The move supports BMY's oncology strategy and partnerships. BMY has a $124.9b market cap and focuses on global drug discovery and development.

Bristol-Myers Squibb (BMY) completed a Phase 1 study in China for BMS-986489, a combination therapy for relapsed small cell lung cancer. The study assessed safety and early anti-tumor activity. The trial's completion suggests potential updates on tolerability and efficacy may be forthcoming, supporting BMY's immuno-oncology pipeline in a key growth market.

Bristol Myers Squibb (BMY) and Pfizer (PFE) face patent expirations but differ in strategy. BMY focuses on oncology and immunology, while PFE pursues high-growth areas via acquisitions. BMY's FY 2025 revenue was $48.2B, net income $7.1B, and PFE's revenue was $62.6B, net income $7.8B. Both face legal and competitive risks, with BMY trading at a higher P/E.

Bristol Myers Squibb (BMY) and Johnson & Johnson (JNJ) are compared. BMY reported $48.2B revenue, $7.1B net income in FY 2025, with a 2.6x debt-to-equity ratio. JNJ reported $94.2B revenue, $26.8B net income, with a 0.6x debt-to-equity ratio. Both face regulatory and litigation risks, but JNJ's diversified business and stronger balance sheet may offer more resilience.

Johnson & Johnson (JNJ), Pfizer (PFE), Merck (MRK), and Bristol Myers Squibb (BMY) are highlighted for their dividend yields and strategies to mitigate patent expiration risks. JNJ raised its dividend to $1.34 per share, with strong cash flow and diversified revenue streams. PFE offers a 6.14% yield but faces significant patent expirations. MRK's dividend is backed by its oncology franchise, while BMY focuses on growth to offset legacy portfolio declines.